Mucosis appoints Dr. Roberto Grimandi as chief med­ical offi­cer

Dutch vac­cine devel­op­ment com­pa­ny MUCOSIS B.V. announced today that Dr. Roberto Grimaldi, MD was appoint­ed Chief Medical Officer at Mucosis. Dr. Grimaldi is an accom­plished exec­u­tive and con­sul­tant to the vac­cine indus­try who brings over 25 years of expe­ri­ence. As an expert on vac­cine devel­op­ment he will lead the Mucosis devel­op­ment pro­grams into clin­i­cal tri­als in the near future.

Before join­ing Mucosis as Chief Medical Officer, Dr. Grimaldi was Executive Vice President at Crucell N.V., respon­si­ble for prod­uct devel­op­ment and reg­u­la­to­ry affairs. He also held respon­si­ble posi­tions amongst oth­ers in Chiron Vaccines, Pharmacia & Upjohn, Sandoz and Farmitalia Carlo Erba. Dr. Grimaldi holds a degree in med­i­cine and surgery from the University of Pavia (Italy), and is spe­cial­ized in clin­i­cal phar­ma­col­o­gy.

“Taking our vac­cine pro­grams into clin­i­cal devel­op­ment is key to Mucosis,” com­ment­ed CEO Govert Schouten. “Our abil­i­ty to attract such a high­ly-expe­ri­enced per­son to lead these efforts gives us fur­ther con­fi­dence in a suc­cess­ful out­come of the var­i­ous pro­grams ongo­ing.”

Mucosis gives pri­or­i­ty to tak­ing its lead prod­uct FluGEM™ into clin­i­cal devel­op­ment. This inno­v­a­tive influen­za vac­cine can be admin­is­tered by a sim­ple spray in the nose. The FluGEM™ pro­gram is par­tic­u­lar­ly direct­ed at achiev­ing bet­ter pro­tec­tion against sea­son­al influen­za in vul­ner­a­ble peo­ple, such as chil­dren and the elder­ly.

Leave a Reply

Your email address will not be published. Required fields are marked *